N/A N=190 Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)
Emphysema
Primary: Forced Expiratory Volume in 1-second (FEV1) — 61; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention
Chronic Myelogenous Leukemia
Primary: Self-reported Fatigue Scores - Change From Baseline Per Scoring Category — 28.03; 24.53; 15.7; 24.7 score on a scale
Phase 2 N=186 Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Primary: Number of Participants With Complete Response — 9; 5; 7; 9 Participants
Phase 4 N=126 Sustaining Remission of Psychotic Depression
Psychotic Depression
Primary: Number of Subjects at Risk of Relapse During the Randomized Phase. — 13; 34 Participants
Phase 2 N=14 Therapeutic Approaches to HAART-Induced Lipodystrophy
HIV Infections · Lipodystrophy
Primary: Fasting Serum Triglycerides — 237; 341 mg/dL — p=0.84
N/A N=59 Exercise and Cognitive Training in Parkinson's Disease
Parkinson's Disease
Primary: Dual Task Function #1 — 1.15; 1.12; .987; 1.068 seconds
Phase 4 N=148 Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus
Type II Diabetes Mellitus
Primary: Changes in the Mean Value of HbA1c — -0.53; -0.01; -0.54; -0.07 percentage of HbA1c — p=0.0002
Phase 2 N=72 Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Breast Cancer
Primary: Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples — -1.3632; -1.6237 log-transformed Ki67% — p=0.6202
Phase 2 N=40 Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)
Complicated Intra-Abdominal Infections, cIAIs
Primary: Plasma Concentration of Aztreonam (ATM): Sparse Sampling at Day 1, 0 hr — 0.1 microgram per milliliter (mcg/mL)
N/A N=15 Comparison of Staples Versus Prolene Suture for Skin Closure at Cesarean Delivery
Pregnancy · Cesarean Section
Primary: Level of Pain on a Scale During the Post-operative Hospitalization Period — 2.0; 2.0 units on a scale — p=0.60
Phase 1 N=43 A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants
N/A N=9 Urology of Virginia Case Series
Prostate Cancer · Cancer of the PROSTATE · Prostatic Neoplasm
Primary: Keyword Description of Each Biopsy Sample — 89 percentage significant cancers detected
Phase 4 N=37 A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination
Idiopathic Pulmonary Fibrosis
Primary: Treatment naïve, Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz). — 150.31…
Phase 2 N=44 Pazopanib as Single Agent in Advanced NETs
Advanced/Metastatic Neuroendocrine Tumors
Primary: Clinical Benefit Rate — 11 Participants
N/A N=53,969 Medical Need of OAC Reversal
Atrial Fibrillation
Primary: The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma. — 14; 35; 84 Number of Patients